Atopic diseases such as atopic eczema are among the most common chronic conditions in children. In a recent study, researchers tested whether a prolonged breastfeeding intervention influenced infants’ risk for eczema during adolescence.

FDA Alerts

FDA Alerts
Tuesday, March 28, 2017
The FDA has approved Regeneron Pharmaceuticals Inc and Sanofi SA's dupilumab (Dupixent) for treatment of moderate to severe atopic dermatitis.
FDA Alerts
Monday, April 25, 2016
The FDA accepted Anacor Pharmaceuticals, Inc’s New Drug Application seeking approval of crisaborole topical ointment, 2%, a novel nonsteroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild to moderate atopic dermatitis.
FDA Alerts
Tuesday, March 22, 2016
FDA accepted for review the New Drug Application (NDA) seeking approval for a new treatment for atopic dermatitis.

NEA Approved Content

NEA Approved Content
Thursday, June 23, 2016
This approach allows patients to receive personalized care from a variety of physicians and health care related professionals to meet their individual needs concerning many issues that patients with atopic dermatitis routinely face.  
NEA Approved Content
Tuesday, May 24, 2016
Posters included recent research covering a variety of aspects of atopic dermatitis.  
NEA Approved Content
Thursday, April 14, 2016
An 18-year-old female presented with skin lesions across her entire body. She complained of itchy, red skin patches with no known triggers. The flaking of her skin and nasal allergies were also worsening.
NEA Approved Content
Wednesday, February 17, 2016
This article highlights several posters presented on eczema at The Winter Clinical Dermatology Conference-Hawaii last month. 

News

News
Friday, November 17, 2017
Atopic diseases such as atopic eczema are among the most common chronic conditions in children. In a recent study, researchers tested whether a prolonged breastfeeding intervention influenced infants’ risk for eczema during adolescence.
News
Friday, November 3, 2017
A recent survey examined the risk of depression and anxiety among patients diagnosed with atopic dermatitis.
News
Thursday, October 26, 2017
An expert panel of the International Eczema Council recently released a statement suggesting when systemic treatment is best for patients with atopic dermatitis.
News
Monday, September 18, 2017
A recent study examined the risk of chemicals that can cause irritation in moisturizers promoted as remedies for skin problems like eczema and labeled as `fragrance-free’ or `hypoallergenic.’

Research in Review

Research in Review
Friday, November 3, 2017
New research data on atopic dermatitis (AD) recently was presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, Switzerland.
Research in Review
Wednesday, November 1, 2017
These programs combine individual patient visits with a group hands-on experience, education, and peer support. 
Research in Review
Wednesday, November 1, 2017

The growing pipeline of therapies for atopic dermatitis has dermatologists optimistic about the future for individuals living with this disease.  

Drug Pipeline

Research in Review
Wednesday, November 1, 2017

Atopic dermatitis (AD), the most common form of eczema, is a chronically relapsing inflammatory skin disease with a complex pathogenesis affecting up to 25% of children in industrialized countries.